BCR-ABL1, Minor (p190), Quantitative by RT-PCR

Patient:	Client:	ARUP Test Code: 2005016
DOB: Age: Gender:		Collection Date: 11/30/2016
Patient Identifiers:	Physician:	Received in lab: 12/01/2016
Visit Number (FIN):		Completion Date: 12/05/2016

Patient Result Summary

Result: Not Detected

***BCR-ABL1/ABL1* Ratio: 0.00000**

BCR-ABL1 fusion transcripts (p190 form) were not detected by RT-qPCR. This result does not exclude the possibility that BCR-ABL1 fusion transcripts (p190 form) are present below the limit of detection for this assay or the presence of other BCR-ABL1 fusion transcripts (p210 or p230 forms) not detected by this assay. This result has been reviewed and approved by , M.D.

Patient History Results

Collected On	Ratio	Result	Source
11/30/16	0.00000	Not Detected	Bone Marrow
09/12/16	0.00000	Not Detected	Not Specified

-See previous individual reports for details on specific test results.
-Historical data is not provided for specimens ordered prior to May 16, 2011.
-Consecutive test results are displayed on this chart; however, this result set may be incomplete due to variations in the demographic information submitted for prior tests. If the information shown on this chart appears incomplete, please consult this patient's prior charts.

Test Information

Background
This assay quantifies BCR-ABL1 transcripts (e1a2) for diagnosis and ongoing therapeutic monitoring. BCR-ABL1 translocations with BCR breakpoints in the minor breakpoint cluster region result in the p190 fusion protein and are predominantly seen in acute lymphoblastic leukemia (ALL) although they may be present in rare cases of chronic myelogenous leukemia (CML).
Methods
Total RNA is isolated and converted to cDNA and BCR-ABL1 fusions are quantitated by real-time PCR amplification. The primers are designed to detect the minor (p190) BCR-ABL1 breakpoint with a fusion between BCR exon 1 and ABL1 exon 2 (e1a2). Each PCR assay includes a standard curve for BCR-ABL1 and the ABL1 control and a normalized copy number (NCN) is calculated (# BCR-ABL1 cDNA molecules/# ABL1 cDNA molecules).
Limitations
The limit of detection of this assay is 1 BCR-ABL1 positive cell in 125,000 normal cells. The results of this test must always be interpreted in the context of morphologic and other relevant data and should not be used alone for a diagnosis of malignancy.
Compliance
Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS